Top Health Tools
Top Health Tools

Top Reports
Top Reports
 
Top Articles
Top Articles

Top Reviews
Top Reviews
   
 
There Are Now 5 FDA-Approved H1N1
Swine Flu Vaccines In The United States

Many have read conflicting reports on which H1N1 vaccines are approved for use in the United States. Here is a summary of the 5 FDA approved H1N1 vaccines, including their ingredients and toxicity.

Analysis of Toxicity, Dosage Recommendations and Usage

2009
H1N1 Monovalent Vaccine (CSL Limited)
 


Toxicity:
No Squalene Present
Beta-Propiolactone: Carcinogen
Neomycin Sulfate: Immunotoxin
Polymyxin B: Neurotoxin
Potassium Chloride: Neurotoxin
Sodium Taurodeoxycholate: Carcinogen/Immunotoxin
Thimerosal: Neurotoxin

Pediatric Use (may lead to toxicity)
Safety and effectiveness in the pediatric population have not been established.

Dosage Recommendations May Lead To Toxicity:
i) Double dosing for children 6 months through 35 months
with two vaccine doses of 0.25ml/dose 4 weeks apart may lead to deadly ethylmercury blood levels causing neurotoxicity.

ii) Double dosing for children 3-9 years of age with two vaccine doses of 0.5ml/dose 4 weeks apart may lead to deadly ethylmercury blood levels causing neurotoxicity.

Pregnancy
Potential harm to fetus not studied or examined.

Nursing Mothers
Potential excretion of toxic ingredients in mother's milk not studied or examined.

Carcinogenesis, Mutagenesis, Impairment of Fertility
No studies on carcinogenic or mutagenic potential or for impairment of fertility.

Pharmacokinetics
Bodily absorption, distribution, metabolism and excretion of any of this vaccine's ingredients have not been studied.

2009
H1N1 Monovalent Vaccine (ID Biomedical Corp of Quebec)
 

Toxicity:
No Squalene Present
Formaldehyde
: Carcinogen
Sodium Deoxycholate: Immunotoxin
Thimerosal: Neurotoxin

Pediatric Use (may lead to toxicity)
Safety and effectiveness in the pediatric population have not been established.

Dosage Recommendations May Lead To Toxicity:
Clinical studies are still ongoing to determine the optimal dosage, number of doses, and schedule for this vaccine.

Pregnancy
Potential harm to fetus not studied or examined.

Nursing Mothers
Potential excretion of toxic ingredients in mother's milk not studied or examined.

Carcinogenesis, Mutagenesis, Impairment of Fertility
No studies on carcinogenic or mutagenic potential or for impairment of fertility.

Pharmacokinetics
Bodily absorption, distribution, metabolism and excretion of any of this vaccine's ingredients have not been studied.


2009
H1N1 Monovalent Vaccine (Novartis)
 

Toxicity:
No Squalene Present
Beta-Propiolactone: Carcinogen
Polymyxin: Neurotoxin
Neomycin: Immunotoxin
Thimerosal: Neurotoxin

Pediatric Use (may lead to toxicity)
Safety and effectiveness in the pediatric population have not been established.

Dosage Recommendations May Lead To Toxicity:
Double dosing for children 4 to 9 years with two vaccine doses of 0.5ml/dose 4 weeks apart may lead to deadly ethylmercury blood levels causing neurotoxicity.

Pregnancy
Potential harm to fetus not studied or examined.

Nursing Mothers
Potential excretion of toxic ingredients in mother's milk not studied or examined.

Carcinogenesis, Mutagenesis, Impairment of Fertility
No studies on carcinogenic or mutagenic potential or for impairment of fertility.

Pharmacokinetics
Bodily absorption, distribution, metabolism and excretion of any of this vaccine's ingredients have not been studied.


2009
H1N1 Monovalent Vaccine (Sanofi Pasteur, Inc.)
 

Toxicity:
No Squalene Present
Formaldehyde : Carcinogen
Polyethylene Glycol: Systemic Toxin
Thimerosal: Neurotoxin
Triton X-100: Systemic Toxin

Pediatric Use (may lead to toxicity)
Safety and effectiveness in the pediatric population have not been established.

Ineffective evaluation protocols in children above 6 months of age. Use may lead to toxicity.

Ineffective adverse event evaluation for this vaccine in all teens/children under 18 years of age. Use may lead to toxicity.

Dosage Recommendations May Lead To Toxicity:
i) Double dosing for children 6 months through 35 months
with two vaccine doses of 0.25ml/dose 4 weeks apart may lead to deadly ethylmercury blood levels causing neurotoxicity.

ii) Double dosing for children 3-9 years of age with two vaccine doses of 0.5ml/dose 4 weeks apart may lead to deadly ethylmercury blood levels causing neurotoxicity.

Pregnancy
Potential harm to fetus not studied or examined.

Nursing Mothers
Potential excretion of toxic ingredients in mother's milk not studied or examined.

Carcinogenesis, Mutagenesis, Impairment of Fertility
No studies on carcinogenic or mutagenic potential or for impairment of fertility.

Pharmacokinetics
Bodily absorption, distribution, metabolism and excretion of any of this vaccine's ingredients have not been studied.


2009
H1N1 Monovalent Vaccine (MedImmune LLC)

Toxicity:
Live Intranasal Virus; No Squalene Present
Monosodium Glutamate: Neurotoxin
Gentamicin Sulfate: Nephrotoxic
Monobasic Potassium Phosphate: Immunotoxin

Pediatric Use (may lead to toxicity)
Safety and effectiveness in the pediatric population have not been established.

Ineffective evaluation protocols in children above 2 years of age. Use may lead to toxicity.

Ineffective adverse event evaluation for this vaccine in all teens/children under 18 years of age. Use may lead to toxicity.

Dosage Recommendations May Lead To Toxicity:
Double dosing for children 2 to 9 years with two vaccine doses of 0.2ml/dose 4 weeks apart may lead to deadly ethylmercury blood levels causing neurotoxicity.

Pregnancy
Potential harm to fetus not studied or examined.

Nursing Mothers
Potential excretion of toxic ingredients in mother's milk not studied or examined.

Carcinogenesis, Mutagenesis, Impairment of Fertility
No studies on carcinogenic or mutagenic potential or for impairment of fertility.

Pharmacokinetics
Bodily absorption, distribution, metabolism and excretion of any of this vaccine's ingredients have not been studied. A biodistribution study of intranasally administered radiolabeled placebo was conducted in 7 healthy adult volunteers. The mean percentage of the delivered doses detected were as follows: nasal cavity 89.7%, stomach 2.6%, brain 2.4%, and lung 0.4%. The clinical significance of these findings is unknown.


Potential Adverse Reactions of all H1N1 Vaccines
  • Pain
  • Redness
  • Swelling
  • Fatigue
  • Headaches
  • Arthralgia (joint inflammation)
  • Myalgia (muscle inflammation)
  • Shivering
  • Sweating
  • Swollen lymph nodes
  • Fever
  • Vomiting
  • Tingling or numbness of the hands or feet
  • Shortness of breath
  • Vasculitis (inflammation of the blood vessels)

Severe Potential Reactions of all H1N1 Vaccines
  • Blood and lymphatic system disorders (lymphadenopathy)

  • Psychiatric disorders (insomnia)

  • Nervous system disorders (dizziness, paraesthesia, inflammation of the central nervous system, inflammation of nerves, autoimmune disorders affecting myelin sheaths of nerves such as Guillain-Barré Syndrome)

  • Ear and labyrinth disorders (vertigo)

  • Respiratory, thoracic and mediastinal disorders (dyspnoea)

  • Gastrointestinal disorders (nausea, diarrhea, abdominal pain, vomiting, dyspepsia, stomach discomfort)

  • Skin and subcutaneous tissue disorders (pruritus, rash)

  • Musculoskeletal and connective tissue disorders (back pain, musculoskeletal stiffness, neck pain, muscle spasms, pain in extremity)

  • General disorders and administration site conditions (bruising, asthenia, chest pain, malaise)

Dave Mihalovic is a Naturopathic Doctor who specializes in vaccine research, cancer prevention and a natural approach to treatment.

* Reports of Adverse Reactions To The H1N1 Vaccine Are Pouring In

* Pregnant Women Refusing H1N1 Vaccine Over Safety Fears

*
Surge in Anaphylactic Shock In B.C. From H1N1 Vaccine

* Reactions Being Reported From Pandemrix H1N1 Swine Flu Vaccine

* A full list of h1n1 vaccine ingredients, alerts and warnings.


Reference Sources FDA
November 19, 2009

Share/Bookmark
...............................................................................................................

This site is owned and operated by PreventDisease.com 1999-2014. All Rights Reserved. All content on this site may be copied, without permission, whether reproduced digitally or in print, provided copyright, reference and source information are intact and use is strictly for not-for-profit purposes. Please review our copyright policy for full details.
aaa
Interact
volunteerDonateWrite For Us
Stay Connected With Our Newsletter